Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$10.9 million.

  • Compass Therapeutics' Free Cash Flow rose 215.41% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year increase of 628.69%. This contributed to the annual value of -$44.9 million for FY2024, which is 1045.81% down from last year.
  • As of Q3 2025, Compass Therapeutics' Free Cash Flow stood at -$10.9 million, which was up 215.41% from -$11.8 million recorded in Q2 2025.
  • Compass Therapeutics' Free Cash Flow's 5-year high stood at -$5.9 million during Q3 2023, with a 5-year trough of -$13.9 million in Q1 2024.
  • Its 3-year average for Free Cash Flow is -$11.0 million, with a median of -$11.1 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Compass Therapeutics' Free Cash Flow was 2589.18% (2024), while the steepest drop was 8703.64% (2024).
  • Compass Therapeutics' Free Cash Flow (Quarter) stood at -$12.4 million in 2023, then increased by 25.89% to -$9.2 million in 2024, then dropped by 18.49% to -$10.9 million in 2025.
  • Its Free Cash Flow stands at -$10.9 million for Q3 2025, versus -$11.8 million for Q2 2025 and -$13.2 million for Q1 2025.